Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Damora Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- 0 vs. Q3 2023
- Shares held
- 3.85M
- −1.60M (−29.3%) vs. Q3 2023
- Total value
- $2.77M
- −$1.15M (−29.3%) vs. Q3 2023
- New holders
- 4
- 3 more added
- Sold out
- 4
- 9 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 2,497,791 | $1.80M | 0.12% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 406,968 | $293.0K | 0.00% | +201,868+98.4% | Added |
| Vanguard Group Inc | 221,200 | $159.3K | 0.00% | +3,900+1.8% | Added |
| Geode Capital Management, LLC | 208,333 | $150.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 123,100 | $88.6K | 0.00% | −50,000−28.9% | Reduced |
| Two Sigma Securities, LLC | 96,927 | $69.8K | 0.00% | +96,927 | New |
| Citadel Advisors LLC | 72,433 | $52.2K | 0.00% | +72,433 | New |
| BlackRock Inc. | 52,106 | $37.5K | 0.00% | −472−0.9% | Reduced |
| State Street Corp | 44,906 | $32.3K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 30,401 | $21.9K | 0.00% | −2,603−7.9% | Reduced |
| Susquehanna International Group, LLP | 27,525 | $19.8K | 0.00% | +27,525 | New |
| Northern Trust Corp | 20,551 | $14.8K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 17,065 | $12.0K | 0.00% | −1,069−5.9% | Reduced |
| Charles Schwab Investment Management Inc | 15,761 | $11.3K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 7,855 | $5.66K | 0.00% | −156−1.9% | Reduced |
| UBS Group AG | 4,280 | $3.08K | 0.00% | −2,808−39.6% | Reduced |
| Spire Wealth Management | 2,000 | $1.32K | 0.00% | +1+0.1% | Added |
| JPMorgan Chase & Co | 849 | $611 | 0.00% | −5−0.6% | Reduced |
| Wells Fargo & Company | 152 | $109 | 0.00% | −322−67.9% | Reduced |
| Morgan Stanley | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 79 | $0 | 0.00% | −13,648−99.4% | Reduced |
| Royal Bank of Canada | 108 | $0 | 0.00% | +108 | New |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −924,788−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −897,657−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −88,580−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −17,307−100.0% | Sold out |